Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs TransMedics Group Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $78.96, while TransMedics Group Inc trades at $70.87 (market cap $2.57B). The key difference: iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| IEMG | TMDX | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $86.00 | $150.42 |
52-Week Low | $59.90 | $61.99 |
Market Cap | — | $2.57B |
Enterprise Value | — | $2.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $77.21, up 0.3% with a bearish technical signal. The ETF shows strong recent performance with 35% one-year returns but faces elevated volatility. Technical indicators show oversold conditions with RSI at 24.55, while moving averages signal bearish momentum. Recent news highlights record inflows into emerging markets and IEMG's 40% technology weighting, particularly in South Korean and Taiwanese semiconductor stocks.
IEMG offers exposure to emerging markets at attractive valuations but carries higher volatility than developed market ETFs. The AI-driven tech concentration provides growth potential but increases sensitivity to sector rotations. Key risks include geopolitical tensions and currency fluctuations, while the low 0.09% expense ratio maintains cost efficiency for long-term investors.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
